Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: Results from a phase 2b, randomized, placebo-controlled, dose-ranging study-MedSci.cn

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: Results from a phase 2b, randomized, placebo-controlled, dose-ranging study

Yamaguchi, Y; Peeva, E; Shore, R

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022; 87 (3): AB105

科室
- - 订阅+
  - 更多科室
工具
服务